A dialogue on analogues Newer vitamin-D drugs for use in bone disease, psoriasis, and cancer

Trends in Endocrinology and Metabolism

Volumn 4, Issue 9, 1993, Pages 297-303

  Jones, Glenville ^a   Calverley, Martin J ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b LEO PHARMA A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; 2BETA (3 HYDROXYPROPOXY)CALCITRIOL; 9,10 SECOCHOLESTA 5,7,10(19),16 TETRAEN 23 YNE 1,3,25 TRIOL; CALBINDIN; CALCIPOTRIOL; CALCITRIOL; CALCIUM; COLLAGEN TYPE 1; DIHYDROTACHYSTEROL; DOXERCALCIFEROL; FALECALCITRIOL; GLUCURONIC ACID; LOW DENSITY LIPOPROTEIN; OSTEOCALCIN; OSTEOPONTIN; PARATHYROID HORMONE; PHOSPHOLIPASE; SEOCALCITOL; TACALCITOL; TAMOXIFEN; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN RECEPTOR;

BONE MINERAL; CALCIUM TRANSPORT; CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; DOSE RESPONSE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYPOCALCEMIA; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PSORIASIS; RECEPTOR BINDING; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 0027137421     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/1043-2760(93)90049-K     Document Type: Article

References (40)

1. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analog of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen
2. 3-25-hydroxylase
3. 3
4. Clinical counterpoint vitamin D-new actions new analogs new therapeutic potential
5. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity
6. Topical calcipotriol treatment in advanced breast cancer
7. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion
8. Vitamin D.
9. Long-term treatment with calcitriol in postmenopausal osteoporosis
10. Two nuclear signalling pathways for vitamin D
11. EB 1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro
12. 3: a role for increased sensitivity to calcium
13. 3 metabolites
14. Vitamin D in the treatment of osteoporosis
15. Vitamin D receptors: nature and function
16. 9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor
17. Metabolism and transporting system of 22-oxacalcitriol (OCT)
18. Vitamin D analogs in the treatment of psoriasis
19. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris
20. 9-C is retinoic acid steroisomer binds and activates the nuclear receptor RXRα
21. 3
22. 3 metabolites on cytosolic free calcium in confluent mouse osteoblasts
23. Baculovirus-mediated expression of the vitamin D receptor
24. 3 to calcitroic acid
25. H-2RIIBP (RXRβ) heterodimerizes with other nuclear hormone receptors and provides a combinatorial mechanism of gene regulation
26. In vitro metabolism of the anti-psoriasic vitamin D analog, calcipotriol, in two cultured human keratinocyte models
27. 3 induces differentiation of human myeloid leukemia cells
28. 3 analogues potently induce the human osteocalcin gene promoter stably transfected into rat osteosarcoma cells (ROSCO-2)
29. Biological potency of a fluorinated vitamin D analog in hypoparathyroidism
30. The development of vitamin D analogues for the treatment of osteoporosis
31. 3: a steroid hormone that produces biologic effects via both genomic and nongenomic pathways
32. In vivo metabolism of the vitamin D analog, dihydrotachysterol
33. 3
34. In vitro metabolism of calcipotriol (MC 903), a vitamin D analogue
35. A monolog on analogs
36. 2 by cultured liver cells
37. 3 analogue, 22-oxacalcitriol (OCT): its different behavior from calcitriol in plasma transport system
38. 3 receptors
39. Newly identified actions of the vitamin D endocrine system
40. 3 prolongs survival time of leukemic mice